Sight Sciences, Inc.

NASDAQ:SGHT

Medical - Devices

Healthcare
$10.77 +2.89%

+$0.15 today

Market cap
$598.59M
Beta
2.40
P/E (TTM)
-7.5
EPS (TTM)
-$0.69
52W Low $3.11High $9.24

Volume 0.34M

Average 0.25M

SGHT Pre-Tax Margin

Income before tax as a percentage of revenue.

Sight Sciences, Inc.NASDAQ: SGHT

Pre-Tax Margin · Q1 FY2026 · quarter ended Mar 2026

Pre-tax margin widens to -65.8%

Pre-tax margin was -65.8% in Q1 FY2026, up 14.8 pp from a year earlier. On a trailing-twelve-month basis it was -46.9%, up 16.1 pp year over year. Over 3 fiscal years it widened by 71.2 pp.

Context

  • Pre-tax margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-65.8%-45.5 pp QoQ
Last fiscal yearDec 2025
-49.7%+14.5 pp YoY
LTMMar 2026
-46.9%+16.1 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+14.8 pp——
1 year+14.5 pp——
3 years+71.2 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
-49.7%
Year-over-year change
+14.5pp

Pre-Tax Margin vs competitors

How SGHT compares with its peers on the latest reported figures

  • SGHT's LTM Mar 2026 pre-tax margin of -46.9% is the 5th highest of the 6 companies compared; the peer median is -6.7%.
  • Its year-over-year change of +16.1 pp is the highest of 6, against a peer median of -9.6 pp.
  • Over three fiscal years its change of +71.2 pp compares with a peer median of +5.2 pp.
SGHT Competitors Peer median
Pre-Tax Margin for SGHT and competitors
Company Period LTM level YoY 3-year change
ALCAlcon Inc.LTM Sep 20267.1% -5.1 pp+5.8 pp
HROWHarrow Health, Inc.LTM Mar 2026-4.2% +6.0 pp+15.2 pp
BHCBausch Health Companies Inc.LTM Jun 2026-6.7% -9.6 pp+5.2 pp
GKOSGlaukos CorporationLTM Jun 2026-31.5% -10.2 pp-3.2 pp
SGHTSight Sciences, Inc.LTM Mar 2026-46.9% +16.1 pp+71.2 pp
OCULOcular Therapeutix, Inc.LTM Mar 2026-558.2% -235.2 pp-375.2 pp
SGPSpyGlass Pharma, Inc. Common StockFY2025— ——
Peer median (excluding SGHT) -6.7%-9.6 pp+5.2 pp

Competitors are the stored peer set for SGHT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue48.96M71.33M81.06M79.87M77.36M
Cost of Revenue8.61M12.36M11.88M11.58M10.7M
Gross Profit40.35M58.97M69.18M68.29M66.67M
Gross Margin82.4%82.7%85.3%85.5%86.2%
Research & Development15.63M22.86M17.56M17.99M14.61M
Selling, General & Admin76.19M120.07M108.89M100.83M89.16M
Operating Expenses91.82M142.92M126.45M118.82M103.77M
Depreciation & Amortization1.2M1.25M614K712K487K
EBITDA(57.21M)(80.48M)(49.42M)(45.9M)(32.79M)
EBITDA Margin-116.8%-112.8%-61.0%-57.5%-42.4%
Operating Income(51.48M)(83.95M)(57.27M)(50.53M)(37.1M)
Operating Margin-105.2%-117.7%-70.7%-63.3%-48.0%
Interest Income00003.97M
Interest Expense4.37M4.47M5.41M4.66M5.14M
Other Income / Expenses(11.29M)(2.24M)1.84M(739K)(1.32M)
Income Before Tax(62.77M)(86.2M)(55.44M)(51.27M)(38.42M)
Pre-Tax Margin-128.2%-120.8%-68.4%-64.2%-49.7%
Income Tax Expense188K47K110K236K10K
Net Income(62.96M)(86.24M)(55.55M)(51.51M)(38.43M)
Net Margin-128.6%-120.9%-68.5%-64.5%-49.7%
EPS (Basic)(1.33)(1.80)(1.14)(1.03)(0.74)
EPS (Diluted)(1.33)(1.80)(1.14)(1.03)(0.74)
Weighted Avg Shares47.5M47.85M48.63M50.13M52.15M
Weighted Avg Shares (Diluted)47.5M47.85M48.63M50.13M52.15M

Sight Sciences, Inc.

NASDAQ:SGHT

Intrinsic Alpha fair value

Locked

Current Price

$10.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.